Stock Expert AI

IDNA ETF — Holdings & Analysis

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an equity ETF with $0.15 billion in assets under management. Launched in 2019, IDNA provides targeted exposure to companies that could benefit from innovation in genomics, immunology, and bioengineering across developed and emerging markets. With an expense ratio of 0.47%, IDNA offers a focused approach to investing in the rapidly evolving healthcare landscape, differentiating itself through its emphasis on genomics and immunology-related companies.

iShares Genomics Immunology and Healthcare ETF (IDNA) ETF — Price, Holdings & Analysis

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an equity ETF with $0.15 billion in assets under management. Launched in 2019, IDNA provides targeted exposure to companies that could benefit from innovation in genomics, immunology, and bioengineering across developed and emerging markets. With an expense ratio of 0.47%, IDNA offers a focused approach to investing in the rapidly evolving healthcare landscape, differentiating itself through its emphasis on genomics and immunology-related companies.

ETF Genel Bakış

The iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.
IDNA aims to capture the growth potential of companies involved in genomics, immunology, and bioengineering. The ETF tracks an index composed of developed and emerging market companies believed to benefit from long-term growth and innovation in these fields. IDNA's portfolio consists of 52 holdings, with a significant allocation to the healthcare sector (97.5%). Top holdings include Moderna Inc (6.57%), Arcellx Inc (4.91%), and Ipsen SA (4.67%), reflecting a focus on innovative pharmaceutical and biotechnology companies. The fund's country exposure is heavily weighted towards the United States (60.5%), followed by France (8.6%) and Germany (7.3%). This targeted approach makes IDNA suitable for investors seeking specialized exposure to the genomics and immunology sub-sectors within the broader healthcare industry.

Risk Metrikleri

IDNA's concentrated sector allocation (97.5% in Healthcare) exposes it to sector-specific risks, meaning that the ETF's performance is highly dependent on the performance of the healthcare industry, particularly genomics and immunology companies. The ETF's beta of 1.35 (3-year) indicates that it is more volatile than the overall market. The fund's expense ratio of 0.47% will create a drag on returns, reducing overall performance by that amount annually. The fund's relatively small AUM of $0.15B could present liquidity risks, especially during periods of market stress. Investors should be aware of these factors when considering an investment in IDNA. Past performance does not guarantee future results.

Gider Oranı

0.47%

En İyi Varlıklar

Sektör Dağılımı

  • Healthcare: 97.5%
  • Cash & Others: 1.7%
  • Industrials: 0.8%
  • United States: 60.5%
  • France: 8.6%
  • Germany: 7.3%
  • Japan: 6.4%
  • Switzerland: 5.6%
  • United Kingdom: 4.1%
  • Denmark: 3.1%
  • China: 2.1%
  • Canada: 0.9%
  • South Korea: 0.8%

Temettü Verimi

0.99%
  • <a href="/etf/xlf">State Street Financial Select Sector SPDR ETF (XLF)</a> — 0.08% expense ratio
  • <a href="/etf/xlk">State Street Technology Select Sector SPDR ETF (XLK)</a> — 0.08% expense ratio
  • <a href="/etf/eem">iShares MSCI Emerging Markets ETF (EEM)</a> — 0.72% expense ratio
  • <a href="/etf/spy">State Street SPDR S&P 500 ETF Trust (SPY)</a> — 0.09% expense ratio
  • <a href="/etf/rwde">Direxion MSCI Developed Over Emerging Markets ETF (RWDE)</a> — 0.53% expense ratio
  • <a href="/etf/fine">Themes European Luxury ETF (FINE)</a> — 0.35% expense ratio
  • <a href="/etf/mj">Amplify Alternative Harvest ETF (MJ)</a> — 0.75% expense ratio
  • <a href="/etf/defa">iShares Adaptive Currency Hedged MSCI EAFE ETF (DEFA)</a> — 0.35% expense ratio
  • <a href="/etf/eem">iShares MSCI Emerging Markets ETF (EEM)</a> (Equity) — 0.72% ER
  • <a href="/etf/defa">iShares Adaptive Currency Hedged MSCI EAFE ETF (DEFA)</a> (Equity) — 0.35% ER
  • <a href="/etf/uae">iShares MSCI UAE ETF (UAE)</a> (Equity) — 0.59% ER
  • <a href="/etf/amca">iShares Russell 1000 Pure U.S. Revenue ETF (AMCA)</a> (Equity) — 0.15% ER
  • <a href="/etf/iwr">iShares Russell Mid-Cap ETF (IWR)</a> (Equity) — 0.18% ER
  • <a href="/etf/iblc">iShares Blockchain and Tech ETF (IBLC)</a> (Equity) — 0.47% ER

Risk Metrikleri

  • Beta: 1.35

Sorular & Cevaplar

What is IDNA and what does it track?

The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. This means IDNA provides investors with exposure to companies involved in cutting-edge research, development, and manufacturing of products and services related to these fields. The fund's top holdings include companies like Moderna Inc and Arcellx Inc, reflecting its focus on innovative healthcare solutions. As of 2026-03-15, IDNA has an AUM of $0.15 billion.

What is the expense ratio for IDNA?

The expense ratio for IDNA is 0.47%. This means that for every $10,000 invested in the ETF, $47 is deducted annually to cover the fund's operating expenses. While this is a cost to consider, it's important to weigh it against the potential benefits of the ETF's focused investment strategy. The expense ratio is slightly higher than some broad market equity ETFs, but it is comparable to other specialized healthcare ETFs. The category average expense ratio is 0.44%.

What are the top holdings in IDNA?

As of 2026-03-15, the top holdings in IDNA are Moderna Inc (6.57%), Arcellx Inc (4.91%), and Ipsen SA (4.67%). These companies represent a significant portion of the ETF's portfolio, reflecting its investment strategy focused on genomics, immunology, and healthcare. The fund also holds Takeda Pharmaceutical Co Ltd (4.46%) and Revolution Medicines Inc Ordinary Shares (4.35%) among its top allocations. These holdings provide insight into the specific companies and industries that IDNA targets within the broader healthcare sector.

Is IDNA a good long-term investment?

Whether IDNA is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and time horizon. IDNA offers targeted exposure to the genomics, immunology, and healthcare sectors, which may experience growth due to technological advancements and demographic trends. However, the ETF's concentration in these sectors also exposes it to sector-specific risks. With a beta of 1.35, IDNA is more volatile than the market. Investors should carefully consider these factors and conduct thorough research before making any investment decisions. Past performance does not guarantee future results.

How does IDNA compare to similar ETFs?

IDNA differentiates itself through its specific focus on genomics, immunology, and healthcare. While other healthcare ETFs may offer broader exposure to the healthcare sector, IDNA targets companies involved in these specific sub-sectors. The fund's expense ratio is 0.47%, which is comparable to other specialized healthcare ETFs. IDNA has an AUM of $0.15 billion, which is smaller than some of the larger healthcare ETFs. Investors should compare IDNA's investment strategy, expense ratio, and AUM to those of other healthcare ETFs to determine which fund best aligns with their investment objectives.

Does IDNA pay dividends?

Yes, IDNA does pay dividends. The current dividend yield for IDNA is 0.99%. This means that for every $100 invested in the ETF, investors can expect to receive $0.99 in dividend payments annually. It's important to note that dividend yields can fluctuate over time due to changes in the ETF's underlying holdings and market conditions. Investors seeking income may find IDNA's dividend yield attractive, but should also consider the ETF's overall investment strategy and risk profile.